AstraZeneca has completed the acquisition of Actavis’ branded respiratory business in the US and Canada for an initial consideration of $600m.
The deal strengthens AstraZeneca’s aclidinium respiratory franchise and builds on the acquisition of Almirall’s respiratory portfolio in 2014 by extending the company’s development and commercialization rights into the US for both Tudorza Pressair and Duaklir Genuair.
{iframe}http://www.pharmaceutical-business-review.com/news/astrazeneca-acquires-rights-to-actavis-lung-drugs-040315-4524623{/iframe}